EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities

EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02Unregistered Sales of Equity Securities.

Story continues below

Issuance of Additional Common Stock In Private Offering

As disclosed in our Current Reports on Form 8-K filed February 21, 2019, February 28, 2019, March 6, 2019, and March 14, 2019 we have previously accepted subscriptions of $3,023,253 for a total of 14,471,474 shares of Common Stock. On March 29, 2019 we accepted additional subscriptions in the total amount $327,016 for an additional 1,113,642 shares of Common Stock. The offer and sale of these shares was made solely to “Accredited Investors” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”). We engaged in no general solicitation or advertising with regard to the offering. Accordingly, the offer and sale of these shares was exempt under Rule 506 of Regulation D under the Securities Act.

Following the issuance of common stock as described above, our total issued and outstanding common stock will be 32,641,884 shares.

Retirement of Note Payable by Issuance of Common Stock

On March 29, 2019, we retired a note payable owing to our former Executive Vice President, Timothy Ryan, in the amount of $30,616. To retire the note, we issued Mr. Ryan shares of common stock valued at $0.20 per share, for a total of 153,080 shares issued to retire the debt.


Exactus, Inc. (Exactus), formerly Spiral Energy Tech, Inc., is a life science company. The Company will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a detection platform. The Company’s primary business focus will be the development and commercialization of the FibriLyzer and related technology licensed by Exactus. The Company’s products will employ a disposable test biosensor strip combined with a portable hand held detection unit that provides a result in approximately 30 seconds. The Company intends to file to gain regulatory approval and launch its products in the United States and Europe.

An ad to help with our costs